Medtronic has completed the acquisition of health care equipment company Intersect ENT, further strengthening its ear, nose and throat (ENT) portfolio.

The deal was first announced last August, when Medtronic agreed to acquire all outstanding Intersect ENT shares for nearly $1.1bn in cash.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

According to a company statement, the acquisition adds Intersect ENT’s PROPEL and SINUVA sinus implant product lines and technology to Medtronic’s portfolio.

Medtronic will also gain related intellectual property and a facility in Menlo Park, California, US.

As part of the deal, Intersect ENT’s workforce will also migrate to the new ownership.

However, former Intersect ENT brand Fiagon and its products, the Cube navigation system and VenSure balloon sinus dilation system, were not included in the deal.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Intersect ENT president and CEO Thomas West said: “We believe the market leadership and global footprint of Medtronic, coupled with enterprise resources to fuel pipeline innovation and commercialisation, will advance our reach to customers and patients more quickly and serve our shared vision of improving patient access, outcomes, and satisfaction for millions of people around the world who suffer from ENT diseases.”

Separately, Medtronic announced that its Onyx Frontier drug-eluting stent (DES) has secured US Food and Drug Administration (FDA) approval.

The Onyx Frontier DES is designed to treat coronary artery disease (CAD). The latest in the Resolute DES family, the stent will help cardiologists address complex coronary cases.

In March, Medtronic announced the first implant of its investigational implantable tibial neuromodulation (TNM) device in a patient for its TITAN 2 pivotal study.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact